Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Neoplasm of Uncertain Histogenesis — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Special Category
Neoplasm of Uncertain Histogenesis

Cancer

Neoplasm of Uncertain Histogenesis

CI-CAN-00000034Explore in graph →

Non-malignant20,280 active trials259 approved drugs3,813 evidence items

NCIt: C6974
OncoTree: MBT
UMLS CUI: C1334936

Overview
Statistics
Survival
Genomics465
Variants & evidence3813
Drugs427
Trials91351
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (4,399)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 3,926–3,950 of 4,399 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Elucidating distinct roles for NF1 in melanomagenesis.
· Cancer Discov · 2013 · PMID 23171796 · validated civic_curation pubmed
Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models.
· Clin Cancer Res · 2013 · PMID 23287563 · validated civic_curation pubmed
The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere.
· J Transl Med · 2013 · PMID 24088382 · validated civic_curation pubmed
Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.
· Mol Cancer Ther · 2012 · PMID 22294718 · validated civic_curation pubmed
MEK targeting in N-RAS mutated metastatic melanoma.
· Mol Cancer · 2014 · PMID 24588908 · validated civic_curation pubmed
Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.
· Cancer Cell · 2015 · PMID 25544636 · validated civic_curation pubmed
Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure.
· Oncogene · 2010 · PMID 20473330 · validated civic_curation pubmed

Showing 3,926–3,950 of 4,399 publications

← Previous
1
…
157
158
159
…
176
Next →

Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts.

· Cancer Res · 2010 · PMID 20354191 · validated civic_curation pubmed

PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.

· Oncogene · 2011 · PMID 21358673 · validated civic_curation pubmed

PI3K pathway dependencies in endometrioid endometrial cancer cell lines.

· Clin Cancer Res · 2013 · PMID 23674493 · validated civic_curation pubmed

LKB1 gene inactivation does not sensitize non-small cell lung cancer cells to mTOR inhibitors in vitro.

· Acta Pharmacol Sin · 2015 · PMID 26027660 · validated civic_curation pubmed

Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin.

· Cancer Res · 2009 · PMID 19706758 · validated civic_curation pubmed

Growth Arrest-Specific 6 (GAS6) Promotes Prostate Cancer Survival by G1 Arrest/S Phase Delay and Inhibition of Apoptosis During Chemotherapy in Bone Marrow.

· J Cell Biochem · 2016 · PMID 27153245 · validated civic_curation pubmed

BET bromodomain inhibition triggers apoptosis of NF1-associated malignant peripheral nerve sheath tumors through Bim induction.

· Cell Rep · 2014 · PMID 24373973 · validated civic_curation pubmed

Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors.

· Cancer Res · 2009 · PMID 19366796 · validated civic_curation pubmed

Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA.

· Exp Hematol · 2014 · PMID 24407160 · validated civic_curation pubmed

Selective inhibition of BET bromodomains.

· Nature · 2010 · PMID 20871596 · validated civic_curation pubmed

ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors.

· Mol Cancer Ther · 2010 · PMID 20124459 · validated civic_curation pubmed

Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay.

· Cancer Res · 2000 · PMID 10866302 · validated civic_curation pubmed

Large-scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors imatinib and crenolanib.

· Clin Cancer Res · 2013 · PMID 24132921 · validated civic_curation pubmed

hVps37A Status affects prognosis and cetuximab sensitivity in ovarian cancer.

· Clin Cancer Res · 2011 · PMID 22016507 · validated civic_curation pubmed

Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.

· Clin Cancer Res · 2012 · PMID 22392911 · validated civic_curation pubmed

PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.

· Cancer Res · 2007 · PMID 18089823 · validated civic_curation pubmed

Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations.

· Exp Hematol · 2014 · PMID 24333121 · validated civic_curation pubmed

Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272.

· Cancer Res · 2006 · PMID 16818618 · validated civic_curation pubmed